{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:52:20Z","timestamp":1790419940942,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T00:00:00Z","timestamp":1681776000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.heliyon.2023.e15638","type":"journal-article","created":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T11:44:28Z","timestamp":1681904668000},"page":"e15638","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["A systematic literature review on the clinical efficacy of low dose naltrexone and its effect on putative pathophysiological mechanisms among patients diagnosed with fibromyalgia"],"prefix":"10.1016","volume":"9","author":[{"given":"Sarah","family":"Partridge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Quadt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Bolton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0062-1216","authenticated-orcid":false,"given":"Jessica","family":"Eccles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlie","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Colasanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0790-7070","authenticated-orcid":false,"given":"Stephen","family":"Bremner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher Iain","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3106-2461","authenticated-orcid":false,"given":"Karin Due","family":"Bruun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6206-485X","authenticated-orcid":false,"given":"Harm","family":"Van Marwijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.heliyon.2023.e15638_bib1","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/acr.20140","article-title":"The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity","volume":"62","author":"Wolfe","year":"2010","journal-title":"Arthritis Care Res."},{"issue":"2","key":"10.1016\/j.heliyon.2023.e15638_bib2","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/art.1780330203","article-title":"The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the multicenter criteria committee","volume":"33","author":"Wolfe","year":"1990","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.heliyon.2023.e15638_bib3","first-page":"g66","volume":"348","author":"Rahman","year":"2014","journal-title":"Fibromyalgia. British Med. J."},{"issue":"8","key":"10.1016\/j.heliyon.2023.e15638_bib4","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s11916-013-0356-5","article-title":"Worldwide epidemiology of fibromyalgia","volume":"17","author":"Queiroz","year":"2013","journal-title":"Curr. Pain Headache Rep."},{"issue":"6","key":"10.1016\/j.heliyon.2023.e15638_bib5","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-010364","article-title":"Prevalence of chronic pain in the UK: a systematic review and meta-analysis of population studies","volume":"16","author":"Fayaz","year":"2016","journal-title":"BMJ Open"},{"issue":"9","key":"10.1016\/j.heliyon.2023.e15638_bib6","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1007\/s00296-017-3725-2","article-title":"Prevalence of fibromyalgia in general population and patients, a systematic review and meta-analysis","volume":"37","author":"Heidari","year":"2017","journal-title":"Rheumatol. Int."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e15638_bib24","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2019-232502","article-title":"Low-dose naltrexone as a treatment for chronic fatigue syndrome","volume":"13","author":"Bolton","year":"2020","journal-title":"BMJ Case Rep."},{"key":"10.1016\/j.heliyon.2023.e15638_bib25","doi-asserted-by":"crossref","first-page":"19","DOI":"10.7861\/clinmed.2020-1009","article-title":"The challenges of chronic pain and fatigue","volume":"21","author":"Eccles","year":"2021","journal-title":"Clin. Med."},{"issue":"2","key":"10.1016\/j.heliyon.2023.e15638_bib36","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2174\/1573397113666170321120329","article-title":"Low dose naltrexone in the treatment of fibromyalgia","volume":"14","author":"Metyas","year":"2018","journal-title":"Curr. Rheumatol. Rev."},{"issue":"2","key":"10.1016\/j.heliyon.2023.e15638_bib44","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines5020016","article-title":"Reduced pro-inflammatory cytokines after eight weeks of low-dose naltrexone for fibromyalgia","volume":"5","author":"Parkitny","year":"2017","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e15638_bib45","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12916-018-1242-0","article-title":"Serious adverse events reported in placebo randomised controlled trials of oral naltrexone: a systematic review and meta-analysis","volume":"17","author":"Bolton","year":"2019","journal-title":"BMC Med."},{"issue":"3","key":"10.1016\/j.heliyon.2023.e15638_bib46","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/phar.2086","article-title":"The Safety and Efficacy of Low-Dose Naltrexone in the Management of Chronic Pain and Inflammation in Multiple Sclerosis, Fibromyalgia, Crohn\u2019s Disease, and Other Chronic Pain Disorders","volume":"38","author":"Patten","year":"2018","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.heliyon.2023.e15638_bib47","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"Mulrow CD. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.heliyon.2023.e15638_bib48","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.heliyon.2023.e15638_bib49","series-title":"Handbook for Grading the Quality of Evidence and the Strength of Recommendations Using the GRADE Approach","year":"2013"},{"issue":"4","key":"10.1016\/j.heliyon.2023.e15638_bib38","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/j.1526-4637.2009.00613.x","article-title":"Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study","volume":"10","author":"Younger","year":"2009","journal-title":"Pain Med."},{"issue":"2","key":"10.1016\/j.heliyon.2023.e15638_bib39","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/art.37734","article-title":"Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels","volume":"65","author":"Younger","year":"2013","journal-title":"Arthritis Rheum."},{"issue":"SUPPL. 3","key":"10.1016\/j.heliyon.2023.e15638_bib40","article-title":"Efficacy of naltrexone in the treatment of fibromyalgia: randomized controlled trial","volume":"72","author":"Abou-Raya","year":"2013","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e15638_bib50","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-055351","article-title":"Study protocol for a randomised, double-blinded, placebo-controlled phase III trial examining the add-on efficacy, cost-utility and neurobiological effects of low-dose naltrexone (LDN) in patients with fibromyalgia (INNOVA study)","volume":"12","author":"Colomer-Carbonell","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.heliyon.2023.e15638_bib51","unstructured":"clinicaltrials.gov. Identifier: NCT02806440: Low Dose Naltrexone for Treatment of Pain in Patients with Fibromyalgia - Effect via a Central Mechanism? (available from: clinicaltrials.gov)."},{"key":"10.1016\/j.heliyon.2023.e15638_bib52","unstructured":"clinicaltrials.gov. Identifier: NCT04502251: LDN and tDCS in Fibromyalgia Available from: clinicaltrials.Gov."},{"issue":"4","key":"10.1016\/j.heliyon.2023.e15638_bib61","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s10067-014-2517-2","article-title":"The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain","volume":"33","author":"Younger","year":"2014","journal-title":"Clin. Rheumatol."},{"issue":"4","key":"10.1016\/j.heliyon.2023.e15638_bib41","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/j.1572-0241.2007.01045.x","article-title":"Low-dose naltrexone therapy improves active Crohn's disease","volume":"102","author":"Smith","year":"2007","journal-title":"Am. J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e15638_bib62","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1186\/s13063-021-05776-7","article-title":"Low-dose naltrexone for the treatment of fibromyalgia: protocol for a double-blind, randomized, placebo-controlled trial","volume":"22","author":"Bruun","year":"2021","journal-title":"Trials"},{"key":"10.1016\/j.heliyon.2023.e15638_bib20","series-title":"Debate Pack: Recognition of Fibromyalgia as a Disability","author":"Barber","year":"2019"},{"key":"10.1016\/j.heliyon.2023.e15638_bib53","series-title":"The British Pain Society. Outcome Measures","year":"2019"},{"key":"10.1016\/j.heliyon.2023.e15638_bib54","article-title":"Are OMERACT recommendations followed in clinical trials on fibromyalgia? A systematic review of patient-reported outcomes and their measures","author":"D\u00f6hmen","year":"2022","journal-title":"Qual. Life Res."},{"issue":"4","key":"10.1016\/j.heliyon.2023.e15638_bib55","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1080\/03007995.2020.1725744","article-title":"The microgabalin ALDAY phase 3 program in pain associated with fibromyalgia: the lessons learned","volume":"36","author":"Merante","year":"2020","journal-title":"Curr. Med. Res. Opin."},{"issue":"10","key":"10.1016\/j.heliyon.2023.e15638_bib56","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1093\/pm\/pnz077","article-title":"Fibromyalgia: an urgent need for harmonized, global, and patient-centric regulatory guidance for developing medications for the treatment of pain and associated symptoms","volume":"20","author":"Merante","year":"2019","journal-title":"Pain Med."},{"key":"10.1016\/j.heliyon.2023.e15638_bib57","doi-asserted-by":"crossref","first-page":"e784","DOI":"10.1097\/PR9.0000000000000784","article-title":"Clinical outcome assessment in clinical trials of chronic pain treatments","volume":"6","author":"Patel","year":"2021","journal-title":"PAIN Reports"},{"issue":"10","key":"10.1016\/j.heliyon.2023.e15638_bib58","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.3899\/jrheum.090367","article-title":"Fibromyalgia syndrome module at OMERACT 9: domain construct","volume":"36","author":"Mease","year":"2009","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.heliyon.2023.e15638_bib59","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.3899\/jrheum.110277","article-title":"OMERACT Fibromyalgia Working Group. Toward development of a fibromyalgia responder index and disease activity score: OMERACT module update","volume":"38","author":"Mease","year":"2011","journal-title":"J. Rheumatol."},{"issue":"2","key":"10.1016\/j.heliyon.2023.e15638_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpain.2007.09.005","article-title":"Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations","volume":"9","author":"Dworkin","year":"2008","journal-title":"J. Pain"}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844023028451?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844023028451?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T10:11:15Z","timestamp":1773396675000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844023028451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S2405844023028451"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2023.e15638","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A systematic literature review on the clinical efficacy of low dose naltrexone and its effect on putative pathophysiological mechanisms among patients diagnosed with fibromyalgia","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2023.e15638","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e15638"}}